Why the study?
Does the dosage of tirofiban and abciximab affect the extent of platelet inhibition and alpha-granule degranulation in patients?
Population
50 patients receiving abciximab or tirofiban
Comparison
Steady-state infusions of abciximab or tirofiban vs Baseline (before infusion)
Design
Cohort
Authors
Loading...
Higher tirofiban dosing enhances platelet inhibition; leaves open optimal regimen for clinical outcomes in CAD.
Does the dosage of tirofiban and abciximab affect the extent of platelet inhibition and alpha-granule degranulation in patients?
Higher dosages of tirofiban (RESTORE dosage) and abciximab provide greater inhibition of platelet reactivity compared to lower dosages (PRISM-PLUS dosage), though significant interindividual variability exists.
Holmes et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: